IYR vs XBI
iShares US Real Estate ETF vs SPDR S&P Biotech ETF
- • XBI has the lower expense ratio at 0.35% vs 0.38% for IYR.
- • IYR pays a higher dividend yield (2.21%).
Side-by-side metrics
| Metric | IYR | XBI |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.38% | 0.35% |
Dividend yield Trailing 12-month yield. | 2.21% | 0.36% |
AUM Assets under management — bigger funds are typically more liquid. | $4.67B | $10.73B |
YTD return | 10.33% | 33.79% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 0.99 | 1.10 |
P/E ratio | 28.45 | — |
Last price | $103.42 | $164.01 |
Inception | — | — |
Issuer | iShares | State Street |
IYR top holdings
| WELL | Welltower Inc | 10.83% |
| PLD | Prologis Inc | 8.73% |
| SPG | Simon Property Group Inc | 4.77% |
| EQIX | Equinix Inc | 4.55% |
| DLR | Digital Realty Trust Inc | 4.38% |
| O | Realty Income Corp | 4.27% |
| AMT | American Tower Corp | 3.85% |
| PSA | Public Storage | 3.72% |
| VTR | Ventas Inc | 3.19% |
| CBRE | CBRE Group Inc Class A | 2.92% |
XBI top holdings
| APGE | Apogee Therapeutics Inc | 1.49% |
| MRNA | Moderna Inc | 1.41% |
| TWST | Twist Bioscience Corp | 1.41% |
| ORKA | Oruka Therapeutics Inc | 1.38% |
| KYMR | Kymera Therapeutics Inc Ordinary Shares | 1.36% |
| VKTX | Viking Therapeutics Inc | 1.30% |
| PRAX | Praxis Precision Medicines Inc Ordinary Shares | 1.29% |
| ERAS | Erasca Inc | 1.27% |
| RVMD | Revolution Medicines Inc Ordinary Shares | 1.20% |
| RYTM | Rhythm Pharmaceuticals Inc | 1.20% |
About IYR
IYR (iShares US Real Estate ETF) is US real estate companies and REITs. Managed by iShares, the fund carries $4.7B in assets under management, an expense ratio of 0.38%, a dividend yield of 2.21%. Its largest holding is Welltower Inc (WELL), which represents 10.8% of the portfolio. Real Estate is the fund's largest sector exposure at 99.5%.
About XBI
XBI (SPDR S&P Biotech ETF) is Equal-weight biotech stocks in the S&P Biotech Index. Managed by State Street, the fund carries $10.7B in assets under management, an expense ratio of 0.35%, a dividend yield of 0.36%. Its largest holding is Apogee Therapeutics Inc (APGE), which represents 1.5% of the portfolio. Financial Services is the fund's largest sector exposure at 0.5%.